ReviewBiomedicines2021
Metabolic Fatty Liver Disease in Children: A Growing Public Health Problem.
Review in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Retrospective analysis of platelet to high-density lipoprotein cholesterol ratio in obese children with metabolic dysfunction-associated fatty liver disease.Translational pediatrics · 2026Article
- The Gut-Liver Axis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Mechanisms, Microbiome Interactions and Therapeutic Targets.Probiotics and antimicrobial proteins · 2026Review
- Retrospective Study of Serum Vitamin D Levels and Metabolic-Associated Fatty Liver Disease in 222 Children and Adolescents Aged 6-18 Years With Obesity.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Serum uric acid/creatinine ratio and metabolic-associated fatty liver disease risks in children.Pediatric research · 2026Article
- Obesity and Resting Metabolic Rate Assessed by Indirect Calorimetry in Pediatric Patients from Northeastern Romania.Diagnostics (Basel, Switzerland) · 2026Article
- Determinants of Liver Steatosis Progression in Chinese Children: A Prospective Cohort Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Role of central and peripheral serotonin in liver physiology and diseases.Theranostics · 2026Review
- Metabolic dysfunction-associated steatotic liver disease in children.Clinical and experimental hepatology · 2025Review
- Development and validation of an online nomogram for screening metabolic-associated fatty liver disease in obese children.Italian journal of pediatrics · 2025Article
- Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders.Current obesity reports · 2025Review
- Trends and Risk Factors of Pediatric Venous Thromboembolism in Spain: A Nationwide Study from 2016 to 2023.Journal of clinical medicine · 2025Article
- High Prevalence of Metabolic-Associated Fatty Liver Disease (MAFLD) in Children and Adolescents with Severe Obesity.Journal of clinical medicine · 2025Article
- Web of Science-Based Visualization of Metabolic Dysfunction-Associated Fatty Liver Disease in Pediatric and Adolescent Populations: A Bibliometric Study.Health science reports · 2025Article
- Drug Advances in NAFLD: Individual and Combination Treatment Strategies of Natural Products and Small-Synthetic-Molecule Drugs.Biomolecules · 2025Review
- Glucagon-Like Peptide-2 as a Potential Biomarker for Nonalcoholic Fatty Liver Disease in Children with Obesity: Preliminary Assessment of Metabolic Associations and Underlying Mechanisms.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- The value of sex hormones and sex hormone-binding globulin in metabolic dysfunction-associated fatty liver disease among boys with obesity.Frontiers in endocrinology · 2025Article
- Serum dihomo-γ-linolenic acid concentration as a potential novel noninvasive biomarker for liver steatosis detection in children.Clinical and experimental hepatology · 2024Article
- Liver magnetic resonance imaging, non-alcoholic fatty liver disease and metabolic syndrome risk in pre-pubertal Mexican boys.Scientific reports · 2024Article
- Association Between Ultraprocessed Food Consumption and Metabolic Disorders in Children and Adolescents with Obesity.Nutrients · 2024Article
- Sex- and gender-based medicine in pediatric nutrition.Italian journal of pediatrics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Metabolic-associated fatty liver disease (MAFLD), previously called nonalcoholic fatty liver diseases (NAFLD), is one of the most important causes of chronic liver disease worldwide and will likely become the leading cause of end-stage liver disease in the decades ahead. MAFLD covers a continuum of liver diseases from fatty liver to nonalcoholic steatohepatitis (NASH), liver fibrosis/cirrhosis and hepatocellular cancer. Importantly, the growing incidence of overweight and obesity in childhood, 4% in 1975 to 18% in 2016, with persisting obesity complications into adulthood, is likely to be harmful by increasing the incidence of severe MAFLD at an earlier age. Currently, MAFLD is the leading form of chronic liver disease in children and adolescents, with a global prevalence of 3 to 10%, pointing out that early diagnosis is therefore crucial. In this review, we highlight the current knowledge concerning the epidemiology, risk factors and potential pathogenic mechanisms, as well as diagnostic and therapeutic approaches, of pediatric MAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.